Analyst Jason McCarthy of Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors related to VistaGen Therapeutics’ promising developments and financial position. The company has reported a net loss but maintains a strong cash position, which is expected to support its operations through mid-2026, including the completion of pivotal studies for its lead drug candidate, fasedienol, in treating social anxiety disorder (SAD).
VistaGen’s ongoing Phase 3 studies, PALISADE-3 and PALISADE-4, are crucial for the company’s future prospects, with data readouts expected in late 2025 and early 2026. A successful outcome from these trials, combined with previous positive results from the PALISADE-2 study, could pave the way for a New Drug Application (NDA) submission. Additionally, the company is advancing its pipeline with other promising candidates, such as PH80 for menopause hot flashes and itruvone for major depressive disorder, further strengthening its position in the market.
In another report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $12.00 price target.